New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
12:51 EDTIAU, FE, LINE, VRTX, CTL, SFDIncreasing implied volatility stocks: SFD VRTX FE CTL LINE IAU
News For SFD;VRTX;FE;CTL;LINE;IAU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
15:14 EDTFESettlement in FirstEnergy rate case may be imminent, Akron Beacon Journal says
A proposed settlement in FirstEnergy's "controversial" rate hike plan may be filed in the next few days, says Akron Beacon Journal. However, the ultimate decision maker in the setttlement will be the Public Utilities Commission of Ohio even if a settlement between Akron-based FirstEnergy and other parties is filed, added Akron Beacon Journal. Reference Link
15:04 EDTFEFirstEnergy mentioned positively at RBC Capital
Subscribe for More Information
November 24, 2015
16:00 EDTFEOptions Update; November 24, 2015
iPath S&P 500 VIX Short-Term Futures up 13c to 19.04, Option volume leaders: AAPL FB NFLX BAC PFE AMZN CHK TWTR GE SUNE DE AGN AAL MSFT INTC X BABA A
07:05 EDTCTLCenturyLink and Cogent sign agreement to connect their public IP networks
Subscribe for More Information
November 23, 2015
08:34 EDTVRTXVertex names Michael J. Parini EVP, chief legal officer
Subscribe for More Information
November 20, 2015
10:34 EDTVRTXVertex approval in Europe to bring gradual uptake, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Vertex Pharmaceuticals must now gain reimbursement in each individual country after the European Union approved Orkambi as expected. The approval will ultimately add around 12,000 homozygous F508del cystic fibrosis patients appropriate for the drug, but uptake will be gradual and dependent on the pace of reimbursement. He reiterates an Overweight rating on Vertex with a $180 price target.
05:36 EDTVRTXVertex receives EU approval for Orkambi
Subscribe for More Information
November 18, 2015
08:14 EDTLINERBC Capital to hold a conference
Subscribe for More Information
05:41 EDTVRTXVertex receives 2 EU approvals for Kalydeco
Vertex Pharmaceuticals announced that the European Commission has approved expansion of the indication for Kalydeco to include children ages 2 to 5 with cystic fibrosis, or CF, who have one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene and to include people with CF ages 18 and older who have an R117H mutation. Ivacaftor was previously approved in the European Union, or EU, for use in people with CF ages 6 and older who have one of nine gating mutations. In Europe, approximately 125 children with CF ages 2 to 5 have one of the nine gating mutations included in today's approval and approximately 350 adults with CF have an R117H mutation. Vertex will now begin the country-by-country reimbursement approval processes for each new indication.
November 16, 2015
07:16 EDTVRTXHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use